ABBV · 10-Q · 2026Q3 · Full report
Neuroscience Market Growth
AbbVie Inc. · 2026-11-03 · Importance 46 · Surprise 56 · In source text
Vraylar net revenues increased 14% in the third quarter and 17% in the first nine months, reflecting market share uptake, market growth and favorable pricing. Botox Therapeutic increased 10% and 12%, respectively, with market growth and continued share uptake cited as drivers. Ubrelvy and Qulipta each posted strong growth, with nine-month net revenues increasing 27% and 39%, respectively, supported by market share uptake and market growth; Vyalev growth exceeded 100% on strong demand uptake. In contrast, global Imbruvica revenues declined 26% in the third quarter and 27% in the first nine months, driven primarily by unfavorable U.S. pricing, lower U.S. demand and decreased collaboration revenues.
Key facts
- Vyalev net revenues increased more than 100% in both the three and nine months ended September 30, 2026, primarily due to strong demand uptake. source
- Qulipta net revenues increased 39% in both the three and nine months ended September 30, 2026, primarily due to market-share uptake and market growth. source
- In June 2026, the European Commission approved Aquipta for acute treatment of migraine in adults with or without aura. source
- In September 2026, AbbVie announced positive topline Phase 3 LUNA results evaluating Qulipta for preventive treatment of menstrual migraine in adults. source
- In September 2026, the FDA approved Juvmo (tavapadon) to treat adults with Parkinson’s disease. source
- Ubrelvy net revenues increased 27% in both the three and nine months ended September 30, 2026, primarily due to market-share uptake, market growth, and favorable pricing. source
- Vraylar net revenues increased 14% in the three months and 17% in the nine months ended September 30, 2026, primarily due to market-share uptake, market growth, and favorable pricing. source
- Botox Therapeutic net revenues increased 10% in the three months and 12% in the nine months ended September 30, 2026, primarily due to market growth and market-share uptake. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | realized | — | Vyalev net revenues increased more than 100% in both the three and nine months ended September 30, 2026, primarily due to strong demand… |
| revenue | positive | realized | — | Qulipta net revenues increased 39% in both the three and nine months ended September 30, 2026, primarily due to market-share uptake and… |